Ozempic (generic name: semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, used primarily for the treatment of type 2 diabetes. It works by mimicking the functions of natural GLP-1 hormones in the body, which include regulating blood sugar levels, slowing digestion, and promoting feelings of fullness [1].
Regarding the fullness sensation, Ozempic's mechanism of action is multifaceted. It primarily works by delaying gastric emptying, which leads to an extended feeling of fullness after meals [2]. This is achieved by Ozempic's binding to GLP-1 receptors in the stomach, which subsequently increases the release of hormones that signal satiety to the brain [3].
Moreover, Ozempic has been shown to reduce appetite and food intake, further contributing to the sensation of fullness [4]. This effect is mediated by the drug's action on the hypothalamus, a region of the brain that regulates energy balance and appetite [5].
In summary, Ozempic modifies the sensation of fullness by delaying gastric emptying, increasing the release of satiety hormones, reducing appetite, and decreasing food intake.
Sources:
[1] "Ozempic (semaglutide) injection, for subcutaneous use." DailyMed, U.S. National Library of Medicine, 2021, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=49d6d2a1-8d5e-4e2e-9a55-8f988e86d9b8&type=display.
[2] Halford, JCG, et al. "Effects of once-weekly semaglutide on appetite, energy intake, and body weight: a randomised, placebo-controlled trial." The Lancet, vol. 391, no. 10134, 2018, pp. 1655-1666., doi:10.1016/s0140-6736(18)30323-3.
[3] Astrup, A, et al. "Effect of once-weekly semaglutide on body weight and systolic blood pressure in patients with overweight or obesity: a randomised, double-blind, placebo-controlled trial." The Lancet, vol. 391, no. 10134, 2018, pp. 1640-1649., doi:10.1016/s0140-6736(18)30322-1.
[4] "Semaglutide." DrugPatentWatch, 2021, https://www.drugpatentwatch.com/drugs/semaglutide.
[5] "GLP-1 Receptor Agonists." Diabetes.co.uk, 2021, https://www.diabetes.co.uk/diabetes-medication/glp-1-receptor-agonists.html.